Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan for cardiac dysfunction in inflammatory cardiomyopathy
2006-006611-68Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of valsartan in heart failure (HF), idiopathic inflammatory cardiomyopathy (IIC) and doxorubicin cardiomyopathy (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Change in ejection fraction at 6 months. Started Apr 2007; status: completed.
02
Drugs
valsartan
03
Conditions
heart failure (HF)idiopathic inflammatory cardiomyopathy (IIC)doxorubicin cardiomyopathy
Beyond the preview
Go deeper on 2006-006611-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006611-68.